Lundbeck has managed to stave off generic medicine producers – for now. The company and its partner, Takeda, have won a legal battle in the US.
The case concerns depression drug Trintellix, which is marketed in the EU as Brintellix. Lundbeck and Takeda started legal proceedings against six generic medicine producers after they submitted approval applications for their copies of Trintellix, which is one of Lundbeck's most important products. The six companies are Alembic, Lupin, Macleouds, Sandoz, Sigmapharm and Zydus.